Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2326 to 2340 of 9128 results

  1. Camizestrant with palbociclib for untreated oestrogen receptor-positive HER2-negative metastatic breast cancer after adjuvant endocrine treatment [ID6534]

    Awaiting development Reference number: GID-TA11686 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Diabetes in pregnancy: management from preconception to the postnatal period - Managing type 1 diabetes (T1D) using hybrid closed loops (update)

    In development Reference number: GID-NG10450 Expected publication date:  20 August 2026

    NICE guideline
    In development

  3. Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]

    In development Reference number: GID-TA11454 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Cosibelimab for treating advanced cutaneous squamous cell carcinoma [ID6663]

    Awaiting development Reference number: GID-TA11883 Expected publication date:  23 September 2027

    Technology appraisal guidance
    Awaiting development

  5. Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies (deferred appraisal of D5) [GID-TA12518]

    In development Reference number: GID-TA12518 Expected publication date:  07 April 2027

    Technology appraisal guidance
    In development

  6. Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]

    In development Reference number: GID-TA11572 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Islatravir–lenacapavir for treating HIV-1 in people with virological suppression on standard HIV-1 treatment [TSID12428]

    Awaiting development Reference number: GID-TA12475 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Iberdomide with dexamethasone and daratumumab for treating relapsed or refractory multiple myeloma after 1 or 2 lines of treatment [TSID12415]

    Awaiting development Reference number: GID-TA12466 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Deucravacitinib for treating systemic lupus erythematosus [TSID12405]

    Awaiting development Reference number: GID-TA12035 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Lotilaner for treating moderate to severe demodex blepharitis

    Awaiting development Reference number: GID-TA12520 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Headaches (update): Prophylactic treatment of migraine - Candesartan

    In development Reference number: GID-NG10472 Expected publication date:  17 February 2027

    NICE guideline
    In development

  12. Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]

    Awaiting development Reference number: GID-TA10823 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]

    Awaiting development Reference number: GID-TA10279 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]

    In development Reference number: GID-TA10497 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Ibrutinib for treating relapsed or refractory follicular lymphoma [ID1251]

    In development Reference number: GID-TA10223 Expected publication date: TBC

    Technology appraisal guidance
    In development